Pay in 4 interest-free payments of $5.33 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Survodutide (BI 456906) is a GLP-1R/GCGR dual agonist developed by Boehringer Ingelheim, with outcomes of a phase 2 trial in MASLD and a phase 1 trial in cirrhosis published almost simultaneously with tirzepatide
Those conditions exist because absorption depends on them
Do not crush, chew, or break
One exception to this restriction is when the approved drug appears on the FDAs shortage list at the time of compounding, distribution, and dispensing
Too high, and you get noise (side effects)
Yes, variants in the GLP1R gene (e.g., rs6923761) have been associated with differences in weight loss response to GLP-1 medications in clinical studies
US$ 22.66
US$ 24.05
US$ 20.94
US$ 21.61
US$ 20.14
US$ 28.63
